|
Cholestasis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Complete obstructive cholestasis due to bile duct ligation for 1 week induced a significant down-regulation of both Svct1 and Svct2 in ileum, whereas Svct2 was up-regulated in liver, and no significant changes in the expression of either transporter were found in kidney, brain or lung.
|
23708151 |
2014 |
|
Cholestasis
|
0.310 |
Biomarker
|
disease |
CTD_human |
When cholestasis was induced in pregnant rats, BVR alpha, SVCT1 and SVCT2 expression in maternal and fetal livers was stimulated, and this was further enhanced by UDCA treatment.
|
18706437 |
2008 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Autistic Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Individual common variants exert weak effects on the risk for autism spectrum disorders.
|
22843504 |
2012 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here we show that the transcription of SVCT2, a major vitamin C transporter, was decreased in human breast cancers (113 cases) compared to normal breast tissues from the same patients.
|
29593282 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The ability of AA to regulate HIF-1α was dependent on SVCT2 function and SVCT2 was not significantly inhibited at pH representative of the tumor microenvironment.
|
28012930 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Moreover, tumor regression via the administration of L-ascorbic acid and cetuximab in mice bearing tumor cell xenografts corresponded to SVCT-2 protein levels.
|
27012422 |
2016 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
A 626 bp band corresponding to a vitamin C transporter (SVCT2) based on the primer design was detected by RT-PCR analysis in all breast cancer cell lines.
|
25102111 |
2014 |
|
Glaucoma, Primary Open Angle
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We have described a novel association between the rs737723 polymorphism (SEC14L2/TAP) and higher POAG risk and confirmed the association between rs1279683 (SLC23A2) and POAG.
|
23401652 |
2013 |
|
Choriocarcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ascorbic acid uptaken by sodium-dependent vitamin C transporter 2 induces βhCG expression through Sp1 and TFAP2A transcription factors in human choriocarcinoma cells.
|
22745243 |
2012 |
|
Glaucoma, Primary Open Angle
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We found a statistically significant association between the rs1279386 (A>G) SNP in SLC23A2 and POAG risk.
|
22171153 |
2011 |
|
Choriocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our observations indicate that SVCT2-mediated AA uptake into cells is necessary for AA-induced steroidogenesis in human choriocarcinoma cell, but MAPK kinase-ERK signaling is not involved in AA-induced steroidogenesis.
|
17901237 |
2008 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C.
|
31467227 |
2020 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tet methylcytosine dioxygenase (Tet2), B-cell lymphoma 2 (Bcl2), and solute carrier family 23 member 2 (Slc23a2) are the major target genes in the treatment of leukemia and are relevant to vitamin C.
|
31467227 |
2020 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
SVCT2 Promotes Neural Stem/Progenitor Cells Migration Through Activating CDC42 After Ischemic Stroke.
|
31607868 |
2019 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We show here that human breast cancer tissues differentially express a form of SVCT2 transporter, that is systematically absent in normal breast tissues and it is increased in breast tumors.
|
30902760 |
2019 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Insufficient uptake of <sub>L</sub>-ascorbic acid in low SVCT-2 expressing cancer cell lines cannot generate sufficient ROS to kill cancer cells, resulting in the hormetic response.
|
30054560 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hormetic dose response to <sub>L</sub>-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression.
|
30054560 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Insufficient uptake of <sub>L</sub>-ascorbic acid in low SVCT-2 expressing cancer cell lines cannot generate sufficient ROS to kill cancer cells, resulting in the hormetic response.
|
30054560 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hormetic dose response to <sub>L</sub>-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression.
|
30054560 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that both fruit intake and genetic marker in SLC23A2 may play an independent role in CLL biology.
|
26838684 |
2017 |
|
Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SVCT2 expression level may serve as a positive outcome predictor for AA treatment in CC.
|
28385602 |
2017 |